Degludec hospital trial: A randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes

Autor: Priyathama Vellanki, David W. Lam, Katherine R. Tuttle, Rodolfo J. Galindo, Maria A. Urrutia, Karla Walkiria Zamudio-Coronado, Limin Peng, Georgia Davis, Maya Fayfman, Citlalli Perez-Guzman, Radica Z. Alicic, Guillermo E. Umpierrez, Alexandra Migdal, Saumeth Cardona, Francisco J. Pasquel
Rok vydání: 2021
Předmět:
Zdroj: Diabetes Obes Metab
ISSN: 1463-1326
1462-8902
DOI: 10.1111/dom.14544
Popis: AIMS: Limited data exists about the use of insulin degludec in the hospital. This multicentre, non-inferiority, open-label, prospective randomised trial compared the safety and efficacy of insulin degludec-U100 and glargine-U100 for the management of hospitalized patients with type 2 diabetes. METHODS: A total of 180 general medicine and surgery patients with an admission blood glucose (BG) between 7·8 – 22·2 mmol/L, treated with oral agents or insulin prior to hospitalization were randomly allocated (1:1) to a basal bolus regimen using degludec (n=92) or glargine (n=88), as basal and aspart before meals. Insulin dose was adjusted daily to a target BG between 3·9 – 10·0 mmol/L. The primary end point was difference in the mean hospital daily BG between groups. RESULTS: Overall, the randomization BG was 12·2 ± 2·9 mmol/L and HbA1c 84 mmol/mol (9·8±2·0%). There were no differences in mean daily BG (10·0±2·1 vs. 10·0±2·5 mmol/L, p=0·9), proportion of BG in target range (54·5± 29% vs. 55·3 ± 28%, p=0·85), basal insulin (29·6 ± 13 vs 30·4 ± 18 units/day, p=0·85), length of stay (median (IQR): 6·7 (4·7–10·5) vs. 7·5 (4·7–11·6) days, p=0·61), hospital complications (23% vs. 23%, p=0·95) between treatment groups. There were no differences in the proportion of patients with BG
Databáze: OpenAIRE
Externí odkaz: